We reviewed 77 cases considered as @entity1072 of intermediate differentiation or @entity706 . Forty-five cases were diagnosed as @entity1073 ( @entity1073 ). The architectural pattern was diffuse in 95%, 8 cases presented large blastoid cells and @entity5893 positivity was observed in 28/34 cases. Of 20 cases studied, 8 presented a t(11;14)(q13;q32). @entity1 characteristics were: median age 59 years, B symptoms in 38%, 87% stages III-IV, bone marrow involvement in 67% with peripheral leukemic cells in 24%. Forty-four @entity1 were treated with chemotherapy and 7 received radiotherapy. The complete response (CR) rate was 58%. Of the 26 CR, 19 relapsed at a median of 15 months. Disease-free survival was 42% and overall survival was 73% at 3 years. In a univariate analysis, overall survival was related to liver and bone marrow involvement, the presence of @entity1897 cells and achieving a complete response.

XXXX : characteristics, natural history and prognostic factors of 45 cases.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity706 :: ('MESH:D008223', 'Disease') :: ['diffuse centrocytic lymphomas'] @entity5893 :: ('921', 'Gene') :: ['CD5'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['lymphocytic lymphomas'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral lymphomatous'] @entity1073 :: ('MESH:D020522', 'Disease') :: ['mantle cell lymphoma', 'MCL']
@entity1073 :: (MESH:D020522,Disease) :: ['Mantle cell lymphomas']
